Cyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer

Journal of Otolaryngology-Head & Neck Surgery

Catherine F Poh²  Scott Durham¹  Donald W Anderson¹  Kelly Y Liu¹  Tarinee Lubpairee²  Rui Jun Lin¹ 

[1] Division of Otolaryngology-Head and Neck Surgery, University of British Columbia, Vancouver, BC, Canada;Integrative Oncology, BC Cancer Agency & Research Centre, Vancouver, BC, Canada

关键词: Prognosis;    Disease free survival;    Cyclin D1;    p16;    Human papillomavirus (HPV);    Oropharyngeal squamous cell carcinoma (OpSCC);   

Others  :  861847
DOI  :  10.1186/1916-0216-42-23

 received in 2012-12-03, accepted in 2013-03-11,  发布年份 2013

【 摘 要 】

Objectives

To determine the biological characteristics of oropharyngeal squamous cell carcinoma (OpSCC) and related outcome.

Design

Retrospective study.

Methods

Patients (N=60) with primary OpSCC from 2000 to 2005 were retrospectively identified from Pathology database and the outcome was confirmed through chart review. Among these, 41 biopsy samples with enough tissues were retrieved to construct a tissue microarray for detection of the presence of high-risk human papillomavirus (HPV) using Chromogenic in situ hybridization (CISH) as well as the expression of p16 and cyclin D1 using immunohistochemistry.

Main outcome measures

Disease-free survival.

Results

Among 60 patients, 39 (65%) patients had no recurrence or died without disease at the last follow-up (disease-free survival or Group 1), and 21 (35%) patients had persistent disease or died of disease (progression-free survival or Group 2). Although follow-up time was twice as long in group 1 (4.7 ± 2.2 vs. 2.0 ± 1.6 years; P < 0.0001), there was no difference between the 2 groups in age, gender, smoking/alcohol habits, TNM staging and treatment modalities. Among those 41 cases with available tumour tissues, there was no difference in HPV status and p16 expression between the 2 groups but a significant difference in cyclin D1 expression (P = 0.05). Using Kaplan-Meir survival analysis and log-rank test, cyclin D1 overexpression was highly associated with a poor prognosis when comparing time to outcome (P < 0.0001).

Conclusion

Cyclin D1 overexpression is a potential prognostic marker of OpSCC.

【 授权许可】

   
2013 Lin et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Chaturvedi AK, Engels EA, Anderson WF, Gillison ML: Incidence trends for human papillomavirus–related and –unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008, 26:612-9.
• [2]Sturgis EM, Ang KK: The epidemic of HPV-associated oropharyngeal cancer is here: is It time to change Our treatment pdigms? J Natl Compr Canc Netw 2011, 9:665-73.
• [3]Chaturvedi AK, Engels EA, Pfeiffer RM: Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J Clin Oncol 2011, 29:4294-301.
• [4]Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-75.
• [5]Herrero R, Castellsagué X, Pawlita M: Human papillomavirus and oral cancer: the international agency for research on cancer multicenter study. J Natl Cancer Inst 2003, 95:1772-83.
• [6]Adelstein DJ, Ridge JA, Gillison ML: Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008. 31st edition. Washington, D.C: Head & Neck; 2009:1393-422.
• [7]Andl T, Kahn T, Pfuhl A: Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998, 58:5-12.
• [8]Li W, Thompson CH, Cossart YE: The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck 2004, 26:1-9.
• [9]Masuda M, Hirakawa N, Nakashima T, Kuratomi Y, Komiyama S: Cyclin D1 overexpression in primary hypopharyngeal carcinomas. Cancer 1996, 78:390-5.
• [10]Edge SBBD, Compton CC: AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.
• [11]Chen B, van den Brekel MWM, Buschers W, Balm AJM, van Velthuysen M-LF: Validation of tissue array technology in head and neck squamous cell carcinoma. Head Neck 2003, 25:922-30.
• [12]O’Regan EM, Toner ME, Finn SP: p16INK4A genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. Hum Pathol 2008, 39:452-8.
• [13]Wang J, Wang X, Gong W, Mi B, Liu S, Jiang B: Increased expression of β-catenin, phosphorylated glycogen synthase kinase 3β, cyclin D1, and c-myc in laterally spreading colorectal tumors. J Histochem Cytochem 2009, 57:363-71.
• [14]Mineta H, Miura K, Takebayashi S: Cyclin D1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma. Oral Oncol 2000, 36:194-8.
• [15]Jares P, Fernández PL, Campo E: PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 1994, 54:4813-7.
• [16]Perisanidis C, Perisanidis B, Wrba F: Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 2012, 41:40-6.
• [17]Smith B, SGLCD: MOlecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001, 127:780-5.
• [18]Michalides R, vVNJKPP: OVerexpression of cyclin d1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1997, 123:497-502.
• [19]Rasamny JJ, Allak A, Krook KA: Cyclin D1 and FADD as Biomarkers in Head and Neck Squamous Cell Carcinoma. Otolaryngology. Head Neck Surg 2012, 146:923-31.
• [20]Hong AM, Dobbins TA, Lee CS: Use of cyclin D1 in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer. Int J Cancer 2011, 128:1532-45.
• [21]Yu Z, Weinberger PM, Haffty BG: Cyclin D1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2005, 11:1160-6.
• [22]Capaccio P, Pruneri G, Carboni N: Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. Head Neck 2000, 22:234-40.
• [23]Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993, 7:812-21.
• [24]Li Y, Nichols MA, Shay JW, Xiong Y: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994, 54:6078-82.
• [25]Rischin D, Young RJ, Fisher R: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 Phase III trial. J Clin Oncol 2010, 28:4142-8.
• [26]Fakhry C, Westra WH, Li S: Improved survival of patients with human papillomavirus–positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100:261-9.
• [27]Ang KK, Harris J, Wheeler R: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.